Sovesudil (PHP-201) is a potent, ATP-competitive, locally acting Rho kinase (ROCK) inhibitor with IC 50 s of 3.7 and 2.3 nM for ROCK-I and ROCK-II, respectively. Sovesudil lowers intraocular pressure (IOP) without inducing hyperemia In Vitro Sovesudil (PHP-201) (1 μM; 60 min) is able to induce altered cellular behavior of human trabecular meshwork (HTM) cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Sovesudil (0.1%, 0.3%, and 0.5%; male New Zealand White rabbits) effectively reduces Intraocular Pressure (IOP) in ocular normotensive and acute hypertensive rabbits without causing distinct hyperemia . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:ROCK-I 3.7 nM (IC 50 ) ROCK-II 2.3 nM (IC 50 )